- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00296218
ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation
Randomized Comparison of a Two-month Regimen of Irbesartan Versus Enalapril on Cardiovascular Markers in Patients With Acute Coronary Syndrome Without ST Segment Elevation.
Primary Objective
- The main objective of this study is to assess if a two-month regimen of irbesartan in patients hospitalized for acute coronary syndrome without ST segment elevation can reduce inflammation markers (ie hsCRP), in comparison to a similar regimen of enalapril.
Secondary Objectives
- To compare both regimens on several other biological parameters which have demonstrated their relevance and their predictive clinical value (ie BNP, microalbuminuria, troponin I …) in this patient population.
- To compare on the above parameters the early initiation of treatment versus the initiation of treatment at hospital discharge.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium
- Sanofi-Aventis
-
-
-
-
-
Laval, Canada
- Sanofi-Aventis
-
-
-
-
-
Paris, France
- Sanofi-Aventis
-
-
-
-
-
Berlin, Germany
- Sanofi-Aventis
-
-
-
-
-
Budapest, Hungary
- Sanofi-Aventis
-
-
-
-
-
Milan, Italy
- Sanofi-Aventis
-
-
-
-
-
Gouda, Netherlands
- Sanofi-Aventis
-
-
-
-
-
Barcelona, Spain
- Sanofi-Aventis
-
-
-
-
-
Meyrin, Switzerland
- Sanofi-Aventis
-
-
-
-
-
Guildford, United Kingdom
- Sanofi-Aventis
-
-
-
-
New Jersey
-
Bridgewater, New Jersey, United States
- Sanofi-Aventis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.
Main criteria are listed hereafter:
Inclusion Criteria
Patient hospitalised with ischemic symptoms (last episode within the last 48 hours before randomization) and at least one of the following characteristics of NSTEACS (non-ST-segment-elevation acute coronary syndromes):
- ECG ST or T changes (ST depression or transient elevation of at least 1mm or T wave changes in at least 2 leads)
- Positive troponin (according to local threshold)
Exclusion Criteria
- Women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the study WOCBP using a prohibited contraceptive method (not applicable)
- Women who are pregnant or breast feeding
- Women with a positive pregnancy test on enrolment or prior to study drug administration
- Patient with dementia
- Persistent ST segment elevation at ECG
- Systolic blood pressure < 100 mmHg
- Bilateral stenosis of renal artery
- Creatinine clearance < or = 30ml/mn
- Congestive heart failure with symptoms consistent with New York Heart Association (NYHA) class III or IV.
- Aortic or mitral valve stenosis
- Hypertrophic cardiomyopathy
- Connective tissue disease with vascular involvement
- Angioplasty, surgery or trauma within the last 3 months
- Coronarography or angioplasty planned to be performed or performed before baseline sampling
- Febrile (≥ 38°C) disease, known concomitant viral or bacterial infection, chronic auto immune disease, chronic inflammatory disease, known cancer in evolution
- Hyperkalemia: serum potassium > 5.5mmol/l
- Sensitivity or intolerance to Angiotensin receptor blockers (ARBs) : olmesartan, candesartan, irbesartan, eprosartan, losartan, telmisartan, valsartan and/or any other ARB currently or previously in development.
- Sensitivity or intolerance to Angiotensin-converting Enzyme Inhibitors (ACE-I) : benazepril, captopril, enalapril, lisinopril, trandolapril, ramipril, quinapril, and/or any other ACE-I currently or previously in development.
- Chronic steroid or non-steroidal anti inflammatory drugs (NSAIDs) use. Aspirin is permitted.
- Treatment with allopurinol or procaïnamide
- Concomitant use of potassium sparing diuretics (eg. spironolactone, triamterene or amiloride), potassium preparations or salt substitutes containing potassium
- Treatment with Lithium
- Immunosupressive medication
- Administration of any other investigational drug in the last 30 days before enrolment and during the course of the study
- Treatment with ARB or ACE inhibitor within the last 3 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
comparison of the relative change from baseline in hsCRP at day 60 between the two treatment groups
|
Secondary Outcome Measures
Outcome Measure |
---|
Relative change from baseline of hsCRP at discharge
|
Changes from baseline in BNP and Microalbuminuria (MAU) at discharge and day 60
|
Change of Troponin I from baseline at discharge
|
In addition at baseline, discharge and D60 the following parameters will be evaluated and their evolution compared in the two treatment groups: IL6, CD 40 L, sPLA2 and Lp-PLA2, IMA, MMP-9, MPO (myeloperoxydase), aldosterone
|
Blood pressure at discharge, D15 and D60.
|
The early versus late (at hospital discharge) initiation of treatment will also be evaluated on the above-listed parameters.
|
& Safety outcomes
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Catherine Domenger, MD, Sanofi
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PM_C_0024
- EudraCT #: 2005-002161-36
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Ischemia
-
Recardio, Inc.CompletedAcute Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Myocardial IschemiaNetherlands, Hungary, Austria, Poland, Belgium
-
University of Roma La SapienzaCompletedRosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs) (ROMA)Periprocedural Myocardial NecrosisItaly
-
Lokien van NunenMaquet Cardiovascular; Stichting Toegepaste Wetenschappen (project number 11052)CompletedAcute Myocardial Infarction | Persisting Ischemia | No ReflowNetherlands
-
University Hospital "Sestre Milosrdnice"CompletedSTEMI - ST Elevation Myocardial Infarction | Myocardial ReperfusionCroatia
-
Tomsk National Research Medical Center of the Russian...CompletedMyocardial Infarction | Myocardial Injury | STEMI | Myocardial NecrosisRussian Federation
-
University Hospital, ToulouseThoratec CorporationWithdrawnChronic Myocardial IschemiaFrance
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Deutsches Herzzentrum MuenchenCompletedInfarction, MyocardialGermany
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
-
Tehran University of Medical SciencesRecruitingMyocardial Infarction | Myocardial Ischemia | Myocardial StunningIran, Islamic Republic of
Clinical Trials on Irbesartan
-
The Affiliated Hospital of Qingdao UniversityCompleted
-
Bristol-Myers SquibbSanofiCompletedHypertensionUnited States, Belgium, Canada, Germany, Russian Federation, France, Israel, Netherlands
-
SanofiCompleted
-
SanofiBristol-Myers SquibbCompletedHypertensionUnited States
-
Steno Diabetes Center CopenhagenCompletedType 2 Diabetes | MicroalbuminuriaDenmark
-
Zhi-Hong Liu, M.D.Terminated
-
Steno Diabetes Center CopenhagenBristol-Myers Squibb; Sanofi-SynthelaboCompletedHypertension | Type 2 Diabetes | Microalbuminuria
-
Travere Therapeutics, Inc.Active, not recruitingImmunoglobulin A NephropathyUnited States, Australia, Belgium, Croatia, Czechia, Estonia, France, Germany, Hong Kong, Italy, Korea, Republic of, Lithuania, New Zealand, Poland, Portugal, Spain, Taiwan, United Kingdom
-
University of Southern DenmarkBristol-Myers SquibbCompleted
-
Jiangsu Famous Medical Technology Co., Ltd.Unknown